Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SADDRIN-1 neoadjuvant AZD1390 with radiotherapy with or without durvalumab in soft tissue sarcoma
NL-OMON56068Phase 1Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of azd1390 and durvalumab in soft tissue sarcoma (STS) (2 arms), sponsored by Netherlands Cancer Institute. Started Jul 2022; status: recruiting.
02
Drugs
azd1390durvalumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON56068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56068.